Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2019
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab
1 February 2019 - Fresenius Kabi announced today that the CHMP of the EMA has issued a positive opinion, recommending marketing ...
Posted by Michael Wonder on 21 Jan 2019
Europe closer to biosimilar rule change, despite fierce resistance from pharma
18 January 2019 - EFPIA says it weakens IP commitment - supporters say it will boost exports. ...
Posted by Michael Wonder on 20 Dec 2018
Biosimilar trastuzumab co-developed by Biocon receives approval in the EU
19 December 2018 - Ogivri, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the EU. ...
Posted by Michael Wonder on 17 Dec 2018
Pfizer receives positive CHMP opinion for oncology biosimilar Zirabev (bevacizumab)
14 December 2018 - Zirabev (bevacizumab), a potential biosimilar to Avastin (bevacizumab), is Pfizer's second therapeutic oncology biosimilar to receive a ...
Posted by Michael Wonder on 03 Dec 2018
Biosimilar pegfilgrastim co-developed by Biocon receives approval in EU
30 November 2018 - Fulphila, a biosimilar pegfilgrastim jointly developed by Biocon and Mylan, has been approved in EU. ...
Posted by Michael Wonder on 03 Dec 2018
Celltrion seeks European approval for Remsima SC
3 December 2018 - South Korean biopharmaceutical firm Celltrion said Monday that it has sought European approval for the sale ...
Posted by Michael Wonder on 27 Nov 2018
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo (pegfilgrastim)
27 November 2018 - Biosimilar Ziextenzo (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in ...
Posted by Michael Wonder on 25 Nov 2018
European Commission approves Pelmeg (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy
23 November 2018 - Pelmeg was developed by Cinfa Biotech, now part of the Mundipharma network of independent associated companies. ...
Posted by Michael Wonder on 07 Nov 2018
AbbVie announces Humira (adalimumab) global patent license with Momenta
6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. ...
Posted by Michael Wonder on 04 Nov 2018
Are rumours of AbbVie's Humira price cuts what they seem?
2 November 2018 - In an effort to combat competition from biosimilar adalimumab products in Europe as patents covering the ...
Posted by Michael Wonder on 01 Nov 2018
AbbVie offers a ‘huge’ discount on Humira to fend off European rivals
1 November 2018 - In hopes of fending off biosimilar competition for its franchise drug, AbbVie has apparently won the ...
Posted by Michael Wonder on 22 Oct 2018
Mylan and Biocon announce positive CHMP opinion for Ogivri, biosimilar trastuzumab
19 October 2018 - Mylan and Biocon today announced that the EMA's CHMP has issued a positive opinion recommending approval ...
Posted by Michael Wonder on 11 Oct 2018
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in ...
Posted by Michael Wonder on 24 Sep 2018
Mylan and Biocon announce positive CHMP opinion for Fulphila, biosimilar pegfilgrastim
21 September 2018 - Mylan and Biocon today announced that the European Medicines Agency's CHMP has issued a positive opinion ...
Posted by Michael Wonder on 24 Sep 2018
Cinfa Biotech receives positive CHMP opinion for Pelmeg (pegfilgrastim), a proposed biosimilar to Neulasta
21 September 2018 - The biosimilar company Cinfa Biotech today announced that the EMA's CHMP has issued a positive opinion recommending ...